sj-tif-2-bcb-10.1177_11782234211056134 – Supplemental material for Ultrastructural Analysis of Inflammatory Breast Cancer Cell Clusters in an Ex Vivo Environment Mechanically Mimicking the Lymph Vascular System

Supplemental material, sj-tif-2-bcb-10.1177_11782234211056134 for Ultrastructural Analysis of Inflammatory Breast Cancer Cell Clusters in an Ex Vivo Environment Mechanically Mimicking the Lymph Vascular System by Yuka Fujii, Savitri Krishnamurthy and Randa El-Zein in Breast Cancer: Basic and Clinical Research</p

sj-tif-1-bcb-10.1177_11782234211056134 – Supplemental material for Ultrastructural Analysis of Inflammatory Breast Cancer Cell Clusters in an Ex Vivo Environment Mechanically Mimicking the Lymph Vascular System

Supplemental material, sj-tif-1-bcb-10.1177_11782234211056134 for Ultrastructural Analysis of Inflammatory Breast Cancer Cell Clusters in an Ex Vivo Environment Mechanically Mimicking the Lymph Vascular System by Yuka Fujii, Savitri Krishnamurthy and Randa El-Zein in Breast Cancer: Basic and Clinical Research</p

Additional file 1: Figure S1. of Micro-anatomical quantitative optical imaging: toward automated assessment of breast tissues

Illustration of methodology used to select MSER intensity parameters. The intensity parameters MaxVariation, MinDiversity, and Delta were selected by varying each parameter one at a time. The area fraction (AF) was calculated for each representative image after each iteration of MSER. Each intensity parameter was plotted as a function of AF. Values for the intensity parameters were selected based on which values correctly isolated nuclei from the representative images and which values led to the largest differences between tumor and benign images. Scale bar 100 Οm. (ZIP 140 kb

Media 1: Toward nodal staging of axillary lymph node basins through intradermal administration of fluorescent imaging agents

Originally published in Biomedical Optics Express on 01 January 2014 (boe-5-1-183

Breast cancer metastasis: challenges and opportunities

Despite exciting progress in the understanding of breast cancerdevelopment and progression, and in the development of noveltherapeutic strategies, breast cancer remains the second leadingcause of cancer-related death in women, with a yearly toll of morethan 40,000 deaths in the United States alone. Breast cancer–relateddeaths are mainly due to the “incurable” nature of metastaticbreast cancer (MBC) at the current time. It is estimated that?6% of patients have metastatic disease at the time of diagnosisand 20% to 50% patients first diagnosed with primary breast cancerwill eventually develop metastatic disease. Even with the remarkableadvances in research and clinical management, thecurrent treatment strategies for breast cancer metastasis stilllargely rely on the use of systemic cytotoxic agents, which frequentlydeteriorate the patient's life quality due to severe sideeffects and, in many cases, have limited long-term success. Theprognosis for MBC patients is poor, with an estimated 5-year survivalof only 26%. Therefore, MBC remains the most challengingtask facing both cancer researcher and oncologist. To tackle thischallenge, scientists and physicians of the Breast Cancer ResearchProgram at the M.D. Anderson Cancer Center held a symposium to(a) provide a better understanding of breast cancer metastasis atthe molecular and cellular level; (b) introduce cutting-edge technologiesin metastatic breast cancer detection, including clinicopathologicdetection, circulating tumor cells (CTC) detection, andadvanced imaging; and (c) solicit innovative ideas in basic, translationalresearch and clinical patient management. The symposiumled to a positive consensus notion that we will be able to prevent,and to a lesser degree, treat metastasis and ultimately save mostpatients from metastatic deaths in the foreseeable future.</p

Supplementary Data from Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer

Supplementary Data from Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cance

Breast cancer metastasis: challenges and opportunities

Despite exciting progress in the understanding of breast cancerdevelopment and progression, and in the development of noveltherapeutic strategies, breast cancer remains the second leadingcause of cancer-related death in women, with a yearly toll of morethan 40,000 deaths in the United States alone. Breast cancer–relateddeaths are mainly due to the “incurable” nature of metastaticbreast cancer (MBC) at the current time. It is estimated that?6% of patients have metastatic disease at the time of diagnosisand 20% to 50% patients first diagnosed with primary breast cancerwill eventually develop metastatic disease. Even with the remarkableadvances in research and clinical management, thecurrent treatment strategies for breast cancer metastasis stilllargely rely on the use of systemic cytotoxic agents, which frequentlydeteriorate the patient's life quality due to severe sideeffects and, in many cases, have limited long-term success. Theprognosis for MBC patients is poor, with an estimated 5-year survivalof only 26%. Therefore, MBC remains the most challengingtask facing both cancer researcher and oncologist. To tackle thischallenge, scientists and physicians of the Breast Cancer ResearchProgram at the M.D. Anderson Cancer Center held a symposium to(a) provide a better understanding of breast cancer metastasis atthe molecular and cellular level; (b) introduce cutting-edge technologiesin metastatic breast cancer detection, including clinicopathologicdetection, circulating tumor cells (CTC) detection, andadvanced imaging; and (c) solicit innovative ideas in basic, translationalresearch and clinical patient management. The symposiumled to a positive consensus notion that we will be able to prevent,and to a lesser degree, treat metastasis and ultimately save mostpatients from metastatic deaths in the foreseeable future.</p

Supplementary Data from Estrogen Receptor β-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer

Supplementary figures 1-8. Supplementary Figure 1. ERβ expression is associated with clinical outcome in IBC patients. Supplementary Figure 2. Associations between ERβ expression and clinical outcome in patients with breast cancer. Supplementary Figure 3. Morphology of IBC cells with different ERβ levels. Supplementary Figure 4. Invasion and migration of IBC cells with different ERβ expression Supplementary Figure 5. ERβ affects metastasis of IBC tumors. Supplementary Figure 6. ERβ regulates genes that control actin cytoskeleton reorganization. Supplementary Figure 7. ERβ regulates genes that are involved in acting cytoskeleton remodeling. Supplementary Figure 8. RhoC and ERβ expression in IBC cells.</p

Supplementary Table 5 from Estrogen Receptor β-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer

Table with patient characteristics</p

Supplementary Table 6 from Estrogen Receptor β-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer

Table with altered genes from microarray analysis</p